SCHEMBL454403

SCHEMBL454403

N#Cc1ccc(C=O)nc1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.42
KDM4E B2RXH2 4/20 0.42
L3MBTL1 Q9Y468 3/20 0.42
FGFR4 P22455 4/20 0.41
KCNJ1 P48048 1/20 0.39
CYP11B2 P19099 2/20 0.38
CYP11B1 P15538 1/20 0.38
LMNA P02545 1/20 0.38
GAA P10253 1/20 0.38
CYP19A1 P11511 1/20 0.36
EGLN2 Q96KS0 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
CCR1 P32246 1/20 0.35
GRM5 P41594 1/20 0.34
HPGD P15428 2/20 0.33
HTT P42858 2/20 0.33
TMPRSS4 Q9NRS4 1/20 0.33
CYP2A6 P11509 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20646150 0.85 CYP11B2 (0.47) CYP11B2CYP11B1
SCHEMBL14508539 0.83 OPRM1 (0.47) ALDH1A1KDM4EL3MBTL1FGFR4GAA
SCHEMBL30547509 0.82 ALDH1A1 (0.39) ALDH1A1KDM4EL3MBTL1FGFR4CYP11B2
SCHEMBL25816595 0.82 ALDH1A1 (0.39) ALDH1A1KDM4EL3MBTL1FGFR4CYP11B2
SCHEMBL31167295 0.79 FGFR4 (0.43) ALDH1A1FGFR4KCNJ1EGLN2CCR1
SCHEMBL286855 0.79 ALDH1A1 (0.42) ALDH1A1KDM4EL3MBTL1FGFR4LMNA
SCHEMBL578235 0.79 FGFR4 (0.43) ALDH1A1FGFR4KCNJ1EGLN2CCR1
SCHEMBL18810357 0.76 MAPT (0.38) ALDH1A1FGFR4KCNJ1KMT2ACCR1
SCHEMBL7371929 0.75 KDM4E (0.49) ALDH1A1KDM4EL3MBTL1LMNAGAA
SCHEMBL1146378 0.75 KDM4E (0.42) ALDH1A1KDM4EL3MBTL1LMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4688785-A1 5-AMINO-6, 8-DIHYDRO-1H-FURO [3, 4-D] PYRROLO [3, 2-B] PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 Beone Medicines I GmbH (CH) 2026-02-11 EP disclosed
US-12528781-B2 Heterocyclic GLP-1 agonists GASHERBRUM BIO, INC. (US) 2026-01-20 US disclosed
US-20250333418-A1 PURINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF NOVO NORDISK AS (DK) 2025-10-30 US disclosed
EP-4608835-A1 PURINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF Novo Nordisk A/S (DK) 2025-09-03 EP disclosed
WO-2025125811-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS Ontrack Therapeutics Limited (GB) 2025-06-19 WO disclosed
CN-120129684-A Purine compound, composition containing same and use thereof 诺和诺德股份有限公司 2025-06-10 CN disclosed
EP-4563571-A1 PRMT5 INHIBITORS Beijing Earthwise Technology Co., Ltd. (CN) 2025-06-04 EP disclosed
US-20250136594-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-05-01 US disclosed
EP-4469438-A1 COMPOUNDS AND METHODS OF USE Tango Therapeutics, Inc. (US) 2024-12-04 EP disclosed
CN-119072474-A Heterocyclic GLP-1 agonists 加舒布鲁姆生物公司 2024-12-03 CN disclosed
EP-1537081-A1 DIHYDROPYRIDINE DERIVATIVES FOR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS Bayer HealthCare AG (DE) 2005-06-08 EP disclosed
WO-2005030734-A1 DIAMINOPYRIMIDINE DERIVATIVES AS SELECTIVE GROWTH HORMONE SECRECTGOGUE RECEPTOR (GHS-R) ANTAGONISTS ABBOTT LABORATORIES (US) 2005-04-07 WO disclosed
US-20050070712-A1 Pyrimidine derivatives as ghrelin receptor modulators ABBOTT LABORATORIES 2005-03-31 US disclosed
WO-2004048352-A2 2-CYANOPYRROLIDINES AND THEIR ANALOGUES AS DPP-IV INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-06-10 WO disclosed
WO-2004020412-A1 DIHYDROPYRIDINE DERIVATIVES FOR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS BAYER HEALTHCARE AG (DE) 2004-03-11 WO disclosed
WO-2003106449-A1 NOVEL ARYL-{4-HALO-4-[HETEROARYLMETHYLAMINO)-METHYL]-PIPERIDIN-1-YL}-METHANONE DERIVATIVES, METHODS FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS PIERRE FABRE MEDICAMENT (FR) 2003-12-24 WO disclosed
EP-1276726-A2 SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS Abbott Laboratories (US) 2003-01-22 EP disclosed
US-20020019527-A1 Substituted phenyl farnesyltransferase inhibitors ABBOTT LABORATORIES 2002-02-14 US disclosed
WO-2001081316-A2 SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS ABBOTT LABORATORIES (US) 2001-11-01 WO disclosed
WO-1998016526-A1 TETRAHYDRO-6H-PYRAZINO[1,2-B]ISOQUINOLINE 1,4-DIONES AS APOPROTEIN B-100 INHIBITORS GLAXO GROUP LIMITED (GB) 1998-04-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136594-A1 COMPOUNDS AND METHODS OF USE CNKSR1, UGT1A1, REV1 ALDH1A1 29/4885KDM4E 1639/4885L3MBTL1 4699/4885
US-20250333418-A1 PURINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF CNR1, CNR2, P2RY1 ALDH1A1 1291/4885KDM4E 3616/4885L3MBTL1 4490/4885
US-12528781-B2 Heterocyclic GLP-1 agonists GLP1R, GIPR, VIP ALDH1A1 3780/4885KDM4E 2887/4885L3MBTL1 3553/4885
US-20050070712-A1 Pyrimidine derivatives as ghrelin receptor modulators GPR119, GIPR, GCGR ALDH1A1 2333/4885KDM4E 1540/4885L3MBTL1 4387/4885
US-20020019527-A1 Substituted phenyl farnesyltransferase inhibitors FNTA, FNTB, SLC10A1 ALDH1A1 385/4885KDM4E 3715/4885L3MBTL1 2965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.